Matthew Maxwell Donley Sells 65,902 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Stock

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) COO Matthew Maxwell Donley sold 65,902 shares of the firm’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total value of $527,216.00. Following the completion of the sale, the chief operating officer now directly owns 739,456 shares of the company’s stock, valued at approximately $5,915,648. This trade represents a 8.18 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Aurinia Pharmaceuticals Stock Up 7.3 %

Aurinia Pharmaceuticals stock opened at $8.67 on Thursday. Aurinia Pharmaceuticals Inc. has a twelve month low of $4.71 and a twelve month high of $10.67. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. The firm has a market cap of $1.24 billion, a PE ratio of -57.80 and a beta of 1.22. The firm’s 50 day moving average price is $8.13 and its two-hundred day moving average price is $7.86.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Invesco Ltd. boosted its position in Aurinia Pharmaceuticals by 1.0% during the fourth quarter. Invesco Ltd. now owns 144,112 shares of the biotechnology company’s stock valued at $1,294,000 after purchasing an additional 1,421 shares during the last quarter. Bridgefront Capital LLC increased its position in Aurinia Pharmaceuticals by 12.9% in the 4th quarter. Bridgefront Capital LLC now owns 16,606 shares of the biotechnology company’s stock worth $149,000 after purchasing an additional 1,891 shares during the last quarter. Cetera Investment Advisers raised its stake in shares of Aurinia Pharmaceuticals by 3.2% during the 4th quarter. Cetera Investment Advisers now owns 64,638 shares of the biotechnology company’s stock worth $580,000 after purchasing an additional 2,000 shares in the last quarter. Teacher Retirement System of Texas lifted its holdings in shares of Aurinia Pharmaceuticals by 5.9% during the 4th quarter. Teacher Retirement System of Texas now owns 36,098 shares of the biotechnology company’s stock valued at $324,000 after buying an additional 2,020 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in shares of Aurinia Pharmaceuticals by 368.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 2,635 shares in the last quarter. 36.83% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, StockNews.com downgraded Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 19th.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.